TerminatedPhase 4

Study Of RV-39 In Patients Who Also Have Asthma

Stopped: lack of data

United States16 participantsStarted 2007-10

Plain-language summary

This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their nose which is known to cause the common cold. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.

Who can participate

Age range18 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have asthma for at least 3 months prior to the study. * Have been using an allowed pre-study asthma therapy for at least 3 months prior to study. * Demonstrate airway hyperresponsiveness following inhalation of bronchoconstrictor. * Have a positive allergic status antibody test. Exclusion Criteria: * Have a history of life-threatening asthma. * Been hospitalized for asthma within the 24 months prior to the study. * Have certain conditions that would make study participation unsafe. * The study doctor will evaluate other inclusion and exclusion criteria.

What they're measuring

Change From Baseline in the Cumulative Lower Respiratory Symptom Score Averaged Over Days 1-4

Timeframe: Days 1 through 4

Trial details

NCT IDNCT00503009

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-07

Results submitted2009-07-06

View on ClinicalTrials.gov More Asthma trials